



**User's Manual**

# Human Haemophilus Influenza B IgG ELISA Kit



DEIA1650



96T



This product is for research use only and is not intended for diagnostic use.

For illustrative purposes only. To perform the assay the instructions for use provided with the kit have to be used.

---

**Creative Diagnostics**

 **Address: 45-1 Ramsey Road, Shirley, NY 11967, USA**

 **Tel: 1-631-624-4882 (USA) 44-161-818-6441 (Europe)**  **Fax: 1-631-938-8221**

 **Email: [info@creative-diagnostics.com](mailto:info@creative-diagnostics.com)**  **Web: [www.creative-diagnostics.com](http://www.creative-diagnostics.com)**

---

## PRODUCT INFORMATION

### Intended Use

Enzyme immunoassay for the determination of IgG antibodies against polyribosylribitolphosphate (PRP) of Haemophilus influenzae type B in human serum and plasma.

### General Description

Haemophilus influenzae type B (HiB) is a very common cause of invasive critical infectious diseases in children up to the age of six. Following infection the symptoms of the disease include: Pericarditis, osteomyelitis, meningitis, encephalitis, pneumonia, sinusitis and otitis. In many cases the disease is lethal or leads to neurological damage, which cannot always be prevented by rapid antibiotic therapy. The underlying reason for the disease is very often a latent immunodeficiency with a specifically reduced humoral immune response to the polyribosylribitolphosphate (PRP) in the polysaccharide encapsulation of the bacterium. In children another reason is the immaturity of the immune system. Today often the term "immunocompromised patients" is used, comprising all acquired and innate specific and unspecific immunodeficiencies.

As a result, in children of 3 months of age or older a vaccination with different sorts of PRP-containing vaccines is recommended. This can lead to a clear reduction in the number of infections with Haemophilus influenzae type B.

The titer of antibodies produced by vaccination can be used to confirm whether the vaccination has been successful. The HiB IgG is used to measure the level of PRP-specific IgG-antibodies following a 4 - 6 weeks period after complete immunization to monitor the humoral immune status of children or other individuals at risk.

Monitoring of the humoral immunostatus after vaccination. Verification of the diagnosis Haemophilus influenzae type B infection by repeated monitoring of antibody concentrations. Risk assessment in immunocompromised patients leading to a failure of vaccination with a PRP-containing vaccine.

This group comprises:

Children under 2 years having had an infection with Haemophilus influenzae type B,

Children with chronic, recurring bacterial infections of the respiratory tract,

Children with chronic otitis,

Patients with confirmed humoral immuno-deficiencies (IgG-2-deficiency, IgA-deficiency),

Patients with confirmed granulocyte deficiencies,

Patients under chemo or cytostatic therapy,

Children after splenectomy,

Patients with sickle-cell anaemia,

Patients with trisomy 21 (Down) syndrome, and certain ethnic groups.

### Principles of Testing

The HiB-IgG is a two-step-ELISA. The wells in the ELISA test strips are coated with PRP. During incubation of diluted serum or plasma samples, specific antibodies against bind to the solid phase (sample incubation). Following a washing procedure, all unbound and non-specific components are washed away.

During the second incubation step, the conjugate reaction, a peroxidase-conjugated anti-human IgG-antibody (anti-human-IgG-HRP) labels the previously specifically bound IgG. In a second washing procedure, unbound conjugate is removed. In a third incubation step, the substrate reaction takes place.

The peroxidase part of the bound conjugate oxidizes tetramethylbenzidine (TMB) to a blue substance. This reaction is stopped by adding sulfuric acid, and the colour changes to yellow. The colour intensity is directly proportional upon the concentration of the PRP-specific antibodies. The absorbance is measured with an ELISA reader at 450 nm. The antibody concentration in the sample can be determined using a reference curve.

## Reagents And Materials Provided

### 1. 1 × 12 × 8, MTP. Microtiter Plate

Coated with PRP from Haemophilus influenzae Typ B. Ready to use!

### 2. 1 × 0.3 mL, ENZCONJ. CONC Conjugate, Concentrate

Anti-human-IgG-peroxidase; colored blue. Dilute before use!

### 3. 5 × 0.35 mL, CAL 1-5. Standard 1-5, Concentrate

Human sera with stabilizers and preservatives. Concentrations are lot specific as indicated on the bottle labels. Dilute before use!

### 4. 2 × 0.35 mL, POS LL, POS HL. Positive Control (Low and High), Concentrate

Positive control sera, LL, "Low Level", HL, "High Level"; for testing accuracy; human sera with stabilizers and preservatives.

Concentrations are lot specific as indicated on the bottle labels.

Dilute before use!

### 5. 2 × 75 mL, DILBUF. Incubation Buffer (Dilution Buffer)

0. 1 M Tris/HCl; pH 7.4; contains detergent; 0.01 % (w/v) thimerosal; colored red. Ready to use!

### 6. 1 × 100 mL, WASHBUF CONC. Wash Buffer, Concentrate (10×)

Contains: phosphate buffer

### 7. 1 × 15 mL, TMB SUBS. TMB Substrate Solution

Substrate solution contains TMB (tetramethylbenzidine). Ready to use!

### 8. 1 × 15 mL, TMB STOP. TMB Stop Solution (0.5 M)

Stop solution, 0.5 M sulphuric acid. Ready to use!

## Materials Required But Not Supplied

1. Micropipettes (Multipette Eppendorf or similar devices, < 3 % CV). Volume: 20; 100; 500; 1000 µL
2. Vortex mixer

3. Tubes for sample dilution
4. 8-Channel Micropipettor with reagent reservoirs
5. Wash bottle, automated or semi-automated microtiter plate washing system
6. Microtiter plate reader capable of reading absorbance at 450 nm (reference wavelength 600-650 nm)
7. Bidistilled or deionised water
8. Paper towels, pipette tips and timer

## Storage

The kit is shipped at ambient temperature and should be stored at 2 - 8°C. Keep away from heat or direct sunlight. The storage and stability of specimens and prepared reagents is stated in the corresponding chapters.

The microtiter strips are stable up to 6 months in the broken, but tightly closed bag when stored at 2 - 8°C.

## Specimen Collection And Preparation

### Human serum, Citrate-, EDTA- or Heparin-Plasma.

The usual precautions for venipuncture should be observed. It is important to preserve the chemical integrity of a blood specimen from the moment it is collected until it is assayed. Do not use grossly hemolytic, icteric or grossly lipemic specimens. Samples appearing turbid should be centrifuged before testing to remove any particulate material.

Storage and Stability: 2 - 8°C (6 weeks), ≤ -20°C (Aliquots) (6 months)

Keep away from heat or direct sunlight. Avoid repeated freeze-thaw cycles.

## Reagent Preparation

### 1. Preparation of Components

Dilute / dissolve	Component	with	Diluent	Relation	Remarks	Storage	Stability
60 µL	ENZCONJ CONC	6 mL	DILBUF	1:101	Mix carefully	2 - 8°C	1 hour
30 mL	WASHBUF CONC	270 mL	bidist. water	1:10	Mix carefully	2 - 8°C	8 weeks

### 2. Dilution of Standards, Controls and Samples

	to be diluted	with	Relation	Remarks
CAL 1-5				
CONTROL LL	generally	DILBUF	1:26	e.g. 20 µL + 500 µL
CONTROL HL				
Serum / Plasma	generally	DILBUF	1:26	e.g. 20 µL + 500 µL

For the determination by standard curve calibrators 1-5 and control sera are needed.

## Assay Procedure

### Assay Note:

1. Any improper handling of samples or modification of the test procedure may influence the results. The indicated pipetting volumes, incubation times, temperatures and pretreatment steps have to be performed

strictly according to the instructions. Use calibrated pipettes and devices only.

2. Once the test has been started, all steps should be completed without interruption. Make sure that required reagents, materials and devices are prepared ready at the appropriate time. Allow all reagents and specimens to reach room temperature (18 - 25°C) and gently swirl each vial of liquid reagent and sample before use. Mix reagents without foaming.
3. Avoid contamination of reagents, pipettes and wells/tubes. Use new disposable plastic pipette tips for each component and specimen. Do not interchange caps. Always cap not used vials. Do not reuse wells/tubes or reagents.
4. It is advised to determine samples in duplicate to be able to identify potential pipetting errors.
5. Use a pipetting scheme to verify an appropriate plate layout.
6. Incubation time affects results. All wells should be handled in the same order and time sequences. It is recommended to use an 8-channel Micropipettor for pipetting of solutions in all wells.
7. Microtiter plate washing is important. Improperly washed wells will give erroneous results. It is recommended to use a multichannel pipette or an automatic microtiter plate washing system. Do not allow the wells to dry between incubations. Do not scratch coated wells during rinsing and aspiration. Rinse and fill all reagents with care. While rinsing, check that all wells are filled precisely with Wash Buffer, and that there are no residues in the wells.
8. Humidity affects the coated wells/tubes. Do not open the pouch until it reaches room temperature. Unused wells/tubes should be returned immediately to the resealed pouch including the desiccant.

#### Procedure:

1. Pipette 100 µL of diluted Calibrator, diluted Controls and diluted sample into the respective wells of the Microtiter Plate.
2. Cover plate with adhesive foil. Incubate 1 h at RT (18 - 25°C).
3. Remove adhesive foil. Discard incubation solution. Wash plate 3 × with 250 µL of diluted Wash Buffer. Remove excess solution by tapping the inverted plate on a paper towel.
4. Pipette 100 µL of diluted Enzyme Conjugate into each well.
5. Cover plate with adhesive foil. Incubate 1 h at RT (18 - 25°C).
6. Remove adhesive foil. Discard incubation solution. Wash plate 3 x with 250 µL of diluted Wash Buffer. Remove excess solution by tapping the inverted plate on a paper towel.
7. For adding of Substrate and Stop Solution use, if available, an 8-channel Micropipettor. Pipetting should be carried out in the same time intervals for Substrate and Stop Solution. Use positive displacement and avoid formation of air bubbles.
8. Pipette 100 µL of TMB Substrate Solution into each well.
9. Incubate 30 min at RT (18 - 25°C).
10. Stop the substrate reaction by adding 100 µL of TMB Stop Solution into each well. Briefly mix contents by gently shaking the plate.
11. Measure optical density with a photometer at 450 nm ± 10 nm (Reference-wavelength: 600 - 650 nm) within 10 min after pipetting of the Stop Solution.

## Quality Control



Tel: 1-631-624-4882 (USA)

Tel: 44-161-818-6441 (Europe)



Fax: 1-631-938-8221



Email: [info@creative-diagnostics.com](mailto:info@creative-diagnostics.com)

The test results are only valid if the test has been performed following the instructions. Moreover, the user must strictly adhere to the rules of GLP (Good Laboratory Practice) or comparable standards/laws.

All kit controls must be found within the acceptable ranges as stated on the labels and the QC certificate.

If the criteria are not met, the run is not valid and should be repeated. Each laboratory should use known samples as further controls.

In case of any deviation the following technical issues should be proven: Expiration dates of (prepared) reagents, storage conditions, pipettes, devices, incubation conditions and washing methods.

It is recommended to participate at appropriate quality assessment trials.

## Calculation

The obtained OD of the standards (y-axis, linear) are plotted against their concentration (x-axis, logarithmic) either on semi-logarithmic graph paper or using an automated method.

x-axis (log): Concentration in [µg/mL]

y-axis (lin): Absorbance (optical density)

A good fit is provided with cubic spline, 4 Parameter Logisitics or Logit-Log.(E.g. 4-Parameter equation 1)

$$\text{Equation 1: } Y = d + (a - d) / (1 + (x/c)^b)$$

For the calculation of the standard curve, apply each signal of the standards (one obvious outlier of duplicates might be omitted and the more plausible single value might be used). The concentration of the samples can be read from the standard curve.

Samples suspected to contain concentrations higher than the highest standard have to be diluted with Diluent Buffer. Measured results must be multiplied with the dilution factor to obtain corrected results.

Concentration values obtained from citrated plasma must be multiplied by 1.1

### Validation criteria:

See QC-certificate

## Reference Values

The determination of PRP-specific antibodies shows the level of humoral immune reaction after an immunization with a PRP-containing vaccine or a clinical apparent or inapparent infection with Haemophilus influenzae type B. When this test is negative and the patient belongs to a risk group (conf. "Indications"), it can be assumed that a risk for an infection with Haemophilus influenzae type B exists.

Humoral immunoreactions after an infection with non-typeable Haemophilus influenzae are not detected by HiB IgG. The failure to seroconvert after vaccination is indicative of the ability to react to bacterial carbohydrate antigens. A polysaccharide-specific immunodeficiency can be observed in patients with chronic bronchitis, recurring pneumoniae, intrinsic bronchial asthma or bronchiectases of unclear genesis.

It has been shown in publications [2, 8, 9, 10, 11] that an antibody concentration under 0.15 µg/mL gives insufficient protection against Haemophilus influenzae type B.

Antibody concentrations between 0.15 and 1.0 µg/mL indicate that the patient has been immunised with PRP or had an infection with HiB.

But only antibody concentrations over 1.0 µg/mL represent a sufficient natural immunity or an acquired protection after the third vaccination.

## Precision

**Intraassay variation:** 2 samples in the concentration range of the calibrators measured 20 times each with one lot in double determination. The intraassay variation was ≤10%.

**Interassay variation:** POS HL and POS LL controls measured in 20 runs on different days with one lot in double determination. The interassay precision was between 9 and 12% respectively. Lower detection limit: ≤ 0.1 µg/mL (lot-specific).

## Precautions

1. For professional use only.
2. Before starting the assay, read the instructions completely and carefully. Use the valid version of the package insert provided with the kit. Be sure that everything is understood.
3. In case of severe damage of the kit package please contact CD or your supplier in written form, latest one week after receiving the kit. Do not use damaged components in test runs, but keep safe for complaint related issues.
4. Obey lot number and expiry date. Do not mix reagents of different lots. Do not use expired reagents.
5. Follow good laboratory practice and safety guidelines. Wear lab coats, disposable latex gloves and protective glasses where necessary.
6. Reagents of this kit containing hazardous material may cause eye and skin irritations.
7. Chemicals and prepared or used reagents have to be treated as hazardous waste according to national biohazard and safety guidelines or regulations.
8. The cleaning staff should be guided by the professionals regarding potential hazards and handling.
9. Avoid contact with Stop solution. It may cause skin irritations and burns.
10. All reagents of this kit containing human serum or plasma have been tested and were found negative for anti-HIV I/II, HBsAg and anti-HCV. However, a presence of these or other infectious agents cannot be excluded absolutely. For this reason reagents should be treated as potential biohazards in use and for disposal.

## References

- [1] Barra, A. et al.: Measurement of Anti-Haemophilus influenzae type B capsular polysaccharide antibodies by ELISA. J. Immunol. Meth. 115, 111 (1988)
- [2] Claesson, BA. et al.: Development of serum antibodies of the immuno-globulin G class and subclasses against the capsular polysaccharide of Haemophilus influenzae type B in children and adults with invasive infections. J. Clin. Microbiol. 26, 2549 (1988)
- [3] Dolan, K.T. et al.: An enzyme-linked immunosorbent assay for quantitation of Haemophilus influenzae type B polysaccharide-specific IgG1 and IgG2 in human and infant rhesus monkey sera. J. Immunoassay 12, 543 (1991)
- [4] Hetherington, S.V. et al.: Correlation between antibody affinity and serum bactericidal activity in infants. J.

Infect. Dis. 165, 753 (1992)

[5] Isaacs, D.: Infectious diseases. Editorial overview. Curr. Opin. Pediat. 4, 45 (1992)

[6] Kristensen, K., Weis Bentzon, M.: Relation between enzyme-linked immunosorbent assay and radioimmunoassay for the detection of antibodies to the capsular polysaccharide of Haemophilus influenzae type B. Acta. path. microbiol. immunol. scand. Sect. C 100, 142 (1992)

[7] Lagergard, T. et al.: Comparison between radioimmunoassay and direct and indirect enzymelinked immunosorbent assay for determination of antibodies against Haemophilus influenzae type B capsular polysaccharide. J. Clin. Microbiol. 26, 2554 (1988)

[8] Käyhty, H. et al.: Antibodies response to capsular polysaccharides of groups A and C Neisseria meningitis and Haemophilus influenzae type b during bacteremic disease. Infect. Dis. 143, 32 (1981)

[9] Anderson, P.: The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type B. J. Infect. Dis. 149, 1034 (1984)

[10] Zielen, S. et al.: Untersuchung zur Effektivität der Haemophilus-influenzae-B-DiphtherieKonjugatimpfung bei deutschen Kindern. Monatsschr. Kinderheilkunde 140, 852 (1992)

[11] Zielen, S., Ahrens, P.: Haemophilus influenzae Typ B-Impfserologie. Ellipse 11, 15 (1994)

[12] Togni, G. u. a.: Präanalytik. Schweiz. Med. Forum. 6, 113-120 (2002)